These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30725091)

  • 1. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
    Coats CJ; Pavlou M; Watkinson OT; Protonotarios A; Moss L; Hyland R; Rantell K; Pantazis AA; Tome M; McKenna WJ; Frenneaux MP; Omar R; Elliott PM
    JAMA Cardiol; 2019 Mar; 4(3):230-235. PubMed ID: 30725091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
    Abozguia K; Elliott P; McKenna W; Phan TT; Nallur-Shivu G; Ahmed I; Maher AR; Kaur K; Taylor J; Henning A; Ashrafian H; Watkins H; Frenneaux M
    Circulation; 2010 Oct; 122(16):1562-9. PubMed ID: 20921440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Maron MS; Masri A; Nassif ME; Barriales-Villa R; Arad M; Cardim N; Choudhury L; Claggett B; Coats CJ; Düngen HD; Garcia-Pavia P; Hagège AA; Januzzi JL; Lee MMY; Lewis GD; Ma CS; Michels M; Olivotto I; Oreziak A; Owens AT; Spertus JA; Solomon SD; Tfelt-Hansen J; van Sinttruije M; Veselka J; Watkins H; Jacoby DL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham TP;
    N Engl J Med; 2024 May; 390(20):1849-1861. PubMed ID: 38739079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
    Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
    JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
    Dybro AM; Rasmussen TB; Nielsen RR; Andersen MJ; Jensen MK; Poulsen SH
    J Am Coll Cardiol; 2021 Dec; 78(25):2505-2517. PubMed ID: 34915981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
    Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
    JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
    Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
    JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.
    Olivotto I; Camici PG; Merlini PA; Rapezzi C; Patten M; Climent V; Sinagra G; Tomberli B; Marin F; Ehlermann P; Maier LS; Fornaro A; Jacobshagen C; Ganau A; Moretti L; Hernandez Madrid A; Coppini R; Reggiardo G; Poggesi C; Fattirolli F; Belardinelli L; Gensini G; Mugelli A
    Circ Heart Fail; 2018 Jan; 11(1):e004124. PubMed ID: 29321131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
    Shah SJ; Voors AA; McMurray JJV; Kitzman DW; Viethen T; Bomfim Wirtz A; Huang E; Pap AF; Solomon SD
    JAMA; 2019 Jun; 321(21):2101-2112. PubMed ID: 31162568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.